Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer
Luz García‐Alonso(Wellcome Sanger Institute), Julio Sáez-Rodríguez(European Bioinformatics Institute), Ian Dunham(Wellcome Sanger Institute), Angela Matchan(Wellcome Sanger Institute), Patricia Jaaks(Wellcome Sanger Institute), Cyril H. Benes(Harvard University), Graham R. Bignell(Lund University), Simon S. McDade(Queen's University Belfast), Francesco Iorio(Human Technopole), Mathew J. Garnett(Wellcome Sanger Institute), Gareth Peat(European Bioinformatics Institute), Nuno A. Fonseca(European Bioinformatics Institute), Miguel Pignatelli(European Bioinformatics Institute), Fiammetta Falcone(Queen's University Belfast)
Cited by 235
Related Papers
Initial sequencing and analysis of the human genome
|Nature|2001|24.6k
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Drug repurposing: progress, challenges and recommendations
|Nature Reviews Drug Discovery|2018|4.6k
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k